intravenous requirements for mr contrast agents

#Intravenous requirements for mr contrast agents trial

Neither Cho nor Cr was detected in the 3 cases of TB. The Cho/Cr ratio for UDC was also higher than for SCC, but this difference was not statistically significant ( p=0.07). The Cho/water ratio for UDC was significantly higher than for SCC ( p=0.04). At TE of 272 ms, spectra were interpretable in 22 of 24 cases and a Cr peak was identified with post-processing in 11 cases. Both Cho/Cr and Cho/water ratios for UDC were significantly higher than SCC ( p=0.002 and 0.026, respectively). The mean ratio for each lesion group was obtained and results were compared statistically.Īt TE of 136 ms, spectra were interpretable in all 24 cases and a Cr peak was identified with post-processing in 15 cases. Cho/Cr and Cho/water ratios were measured for each lesion. A point-resolved spectroscopic sequence with echo times (TE) of 136 and 272 ms and a time-domain spectral fitting procedure were used to estimate peak amplitude of choline (Cho), creatine (Cr) and unsuppressed water. 3 with tuberculosis (TB) and 1 with Castleman's disease.

Cervical lymphadenopathy was also examined in 4 individuals with benign disease, i.e. 10 with squamous cell carcinoma (SCC), 6 with undifferentiated carcinoma (UDC) and 4 with non-Hodgkin's lymphoma (NHL). To evaluate the feasibility of performing in vivo proton magnetic resonance spectroscopy ( 1H-MRS) of cervical lymph nodes, and the clinical usefulness of the technique in the characterization of cervical lymphadenopathy.Ĭervical lymphadenopathy was examined in 20 individuals with malignant disease, i.e. On T2-weighted images there was statistically improved efficacy at the intermediate dose, which did not improve at the highest dose.ĬONCLUSION: Ultrasmall superparamagnetic iron oxide was an effective contrast agent for liver MR imaging at all doses and a dose of 1.1 mg Fe/kg was recommended for future clinical trials.Saini, S. On T2-weighted images metastases increased in contrast relative to normal hepatic parenchyma whereas haemangiomas decreased in contrast. Signal intensity analysis revealed that all three doses increased liver SI on T1-weighted images and decreased liver SI on T2-weighted images. The results with all three doses were statistically significant ( P < 0.05). RESULTS: Post-contrast medium MR imaging showed additional information in 71/97 patients (73%) for reader one and 83/96 patients (86%) for reader two. Signal intensity (SI) based quantitative measurements were also taken. Images were analysed by two independent readers for additional information (lesion detection, exclusion, characterization and patient management). Liver MR imaging was performed before and after USPIO with T1-weighted and T2-weighted pulse sequences. MATERIAL AND METHODS: Ninety-nine patients with focal liver lesions received USPIO at a dose of 0.8 ( n = 35), 1.1 ( n = 32), or 1.7 ( n = 32) mg Fe/kg.

#Intravenous requirements for mr contrast agents trial

AIM: A dose ranging multicentre phase-II clinical trial was conducted to evaluate the efficacy of ultrasmall superparamagnetic iron oxide (USPIO) ferumoxtran-10 for magnetic resonance (MR) imaging of focal hepatic lesions.